Gossamer Bio Announces GB1275 Data Presentations at 2020 Society for Immunotherapy of Cancer Annual Meeting
November 06 2020 - 7:03AM
Business Wire
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage
biopharmaceutical company focused on discovering, acquiring,
developing and commercializing therapeutics in the disease areas of
immunology, inflammation and oncology, today announced that it will
present data relevant to GB1275 at the 35th Annual Meeting of the
Society for Immunotherapy of Cancer (SITC), to be held virtually
from November 9-14, 2020. This includes clinical and biomarker data
from the ongoing GB1275 Phase 1/2 clinical trial, KEYNOTE-A36, in
advanced solid tumors and corresponding presentations from Johanna
Bendell, M.D. and Wells Messersmith, M.D.
Details for presentations related to GB1275, a CD11b
modulator in clinical development for the treatment of solid
tumors, are as follows:
Poster Title: Preliminary results from KEYNOTE-A36, a
study of GB1275, a first-in-class oral CD11b modulator, alone and
with pembrolizumab or chemotherapy in specified advanced solid
tumors Poster / Abstract Number: 388 Presenting
Author: Johanna Bendell, M.D.
Poster Title: Combining transcriptomic- and tissue-based
immune biomarkers to evaluate GB1275, a CD11b modulator, as a
single agent or with pembrolizumab in patients with advanced solid
tumors Poster / Abstract Number: 389 Presenting
Author: Wells Messersmith, M.D.
Posters can be accessed on the SITC website on Monday, November
9th at 8:00 a.m. EST. The posters will also be made available in
the “Posters and Publications” section of the Gossamer Bio website
at gossamerbio.com.
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company
focused on discovering, acquiring, developing and commercializing
therapeutics in the disease areas of immunology, inflammation and
oncology. Its goal is to be an industry leader in each of these
therapeutic areas and to enhance and extend the lives of patients
suffering from such diseases.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201106005092/en/
For Investors and Media: Bryan Giraudo, Chief Financial
Officer Gossamer Bio Investor Relations ir@gossamerbio.com
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Apr 2023 to Apr 2024